Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
18
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 18 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Arikayce Amikacin Liposomal/Neb.Accessr | D | $187M | +16% | 2,647 | $70,670 | $64.22 |
| Serostim Somatropin | D | $110M | +2% | 612 | $178,947 | $684.07 |
| Monoferric Ferric DerIsomaltose · J1437 | B | $108M | +55% | 41,968 | $2,572 | $19.82 |
| Onivyde Irinotecan Liposomal · J9205 | B | $87.9M | +19% | 2,165 | $40,586 | $62.10 |
| Somatuline Depot Lanreotide Acetate | D | $57.7M | +9% | 910 | $63,440 | $21,089.27 |
| Somavert PEGvisomant | D | $37.3M | +1% | 257 | $145,112 | $533.93 |
| Genotropin Somatropin | D | $26.8M | -1% | 1,495 | $17,930 | $625.62 |
| Norditropin Flexpro Somatropin | D | $16.4M | +48% | 779 | $21,033 | $1,069.83 |
| Doxil* Doxorubicin HCL Peg-Liposomal* · Q2050 | B | $14.5M | +9% | 5,519 | $2,635 | $114.96 |
| Omnitrope Somatropin | D | $9.6M | -3% | 702 | $13,609 | $491.97 |
| Humatrope Somatropin | D | $6.1M | -2% | 286 | $21,374 | $1,462.35 |
| Nutropin Aq Nuspin Somatropin | D | $3.9M | -30% | 226 | $17,398 | $593.14 |
| Onivyde Irinotecan Liposomal | D | $2.2M | +64% | 47 | $47,526 | $275.43 |
| Soma Carisoprodol | D | $1.5M | -5% | 237 | $6,192 | $10.08 |
| Sogroya Somapacitan-Beco | D | $1.4M | +732% | 91 | $14,916 | $1,316.45 |
| Doxorubicin HCl Liposome Doxorubicin HCl PEG-Liposomal | D | $427K | -26% | 65 | $6,576 | $52.80 |
| Skytrofa Lonapegsomatropin-Tcgd | D | $159K | n/a | n/a | n/a | $1,802.83 |
| Zomacton Somatropin | D | $62K | -10% | n/a | n/a | $515.45 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.